These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34737134)

  • 1. Employing an adverse outcome pathway framework for weight-of-evidence assessment with application to the ICH S1B guidance addendum.
    Stalford SA; Cayley AN; de Oliveira AAF
    Regul Toxicol Pharmacol; 2021 Dec; 127():105071. PubMed ID: 34737134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing chemical carcinogenicity: hazard identification, classification, and risk assessment. Insight from a Toxicology Forum state-of-the-science workshop.
    Felter SP; Bhat VS; Botham PA; Bussard DA; Casey W; Hayes AW; Hilton GM; Magurany KA; Sauer UG; Ohanian EV
    Crit Rev Toxicol; 2021 Sep; 51(8):653-694. PubMed ID: 35239444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory Forum commentary: alternative mouse models for future cancer risk assessment.
    Morton D; Sistare FD; Nambiar PR; Turner OC; Radi Z; Bower N
    Toxicol Pathol; 2014 Jul; 42(5):799-806. PubMed ID: 23965809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncertainties of testing methods: What do we (want to) know about carcinogenicity?
    Paparella M; Colacci A; Jacobs MN
    ALTEX; 2017; 34(2):235-252. PubMed ID: 27776202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory Forum.
    Peden WM
    Toxicol Pathol; 2016 Dec; 44(8):1069-1071. PubMed ID: 27753636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proposed integrated decision-tree testing strategies for mutagenicity and carcinogenicity in relation to the EU REACH legislation.
    Combes R; Grindon C; Cronin MT; Roberts DW; Garrod J
    Altern Lab Anim; 2007 May; 35(2):267-87. PubMed ID: 17559315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory Forum Opinion Piece*: Transgenic/Alternative Carcinogenicity Assays: A Retrospective Review of Studies Submitted to CDER/FDA 1997-2014.
    Jacobs AC; Brown PC
    Toxicol Pathol; 2015 Jul; 43(5):605-10. PubMed ID: 25630682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a network of carcinogenicity adverse outcome pathways and its employment as an evidence framework for safety assessment.
    Cayley AN; Foster RS; Hill E; Kane S; Kocks G; Myden A; Newman D; Stalford SA; Vessey JD; Zarei R; De Oliveira AAF
    ALTEX; 2023; 40(1):34–52. PubMed ID: 35575642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of alternative methods of carcinogenicity testing and evaluation of human pharmaceuticals.
    Van Deun K; Van Cauteren H; Vandenberghe J; Canning M; Vanparys P; Coussement W
    Adverse Drug React Toxicol Rev; 1997 Nov; 16(4):215-33. PubMed ID: 9608857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical carcinogen safety testing: OECD expert group international consensus on the development of an integrated approach for the testing and assessment of chemical non-genotoxic carcinogens.
    Jacobs MN; Colacci A; Corvi R; Vaccari M; Aguila MC; Corvaro M; Delrue N; Desaulniers D; Ertych N; Jacobs A; Luijten M; Madia F; Nishikawa A; Ogawa K; Ohmori K; Paparella M; Sharma AK; Vasseur P
    Arch Toxicol; 2020 Aug; 94(8):2899-2923. PubMed ID: 32594184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rethinking chronic toxicity and carcinogenicity assessment for agrochemicals project (ReCAAP): A reporting framework to support a weight of evidence safety assessment without long-term rodent bioassays.
    Hilton GM; Adcock C; Akerman G; Baldassari J; Battalora M; Casey W; Clippinger AJ; Cope R; Goetz A; Hayes AW; Papineni S; Peffer RC; Ramsingh D; Williamson Riffle B; Sanches da Rocha M; Ryan N; Scollon E; Visconti N; Wolf DC; Yan Z; Lowit A
    Regul Toxicol Pharmacol; 2022 Jun; 131():105160. PubMed ID: 35311659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory Forum Opinion Piece: Carcinogen Risk Assessment: The Move from Screens to Science.
    Downes N; Foster J
    Toxicol Pathol; 2015 Dec; 43(8):1064-73. PubMed ID: 26296629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A feasibility study: Can information collected to classify for mutagenicity be informative in predicting carcinogenicity?
    Petkov PI; Patlewicz G; Schultz TW; Honma M; Todorov M; Kotov S; Dimitrov SD; Donner EM; Mekenyan OG
    Regul Toxicol Pharmacol; 2015 Jun; 72(1):17-25. PubMed ID: 25792138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated Approaches to Testing and Assessment: OECD Activities on the Development and Use of Adverse Outcome Pathways and Case Studies.
    Sakuratani Y; Horie M; Leinala E
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():20-28. PubMed ID: 29316278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Conference on Harmonisation: guidance on testing for carcinogenicity of pharmaceuticals. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Feb; 63(35):8983-6. PubMed ID: 12269370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving carcinogenicity assessment.
    Morton D; Bourcier T; Alden CL
    Toxicol Pathol; 2013 Feb; 41(2):263-70. PubMed ID: 23076039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is current risk assessment of non-genotoxic carcinogens protective?
    Braakhuis HM; Slob W; Olthof ED; Wolterink G; Zwart EP; Gremmer ER; Rorije E; van Benthem J; Woutersen R; van der Laan JW; Luijten M
    Crit Rev Toxicol; 2018 Jul; 48(6):500-511. PubMed ID: 29745287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Conference on Harmonisation; proposed change to rodent carcinogenicity testing of pharmaceuticals; request for comments. Notice; request for comments.
    Food and Drug Administration, HHS
    Fed Regist; 2013 Mar; 78(52):16681-4. PubMed ID: 23530289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vivo rodent test systems for assessment of carcinogenic potential.
    van der Laan JW; Spindler P
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.